
1. j acquir immune defic syndr. 2003 feb 1;32(2):170-81.

effect cessation zidovudine prophylaxis reduce vertical transmission 
maternal hiv disease progression survival.

bardeguez ad(1), shapiro de, mofenson lm, coombs r, frenkel lm, fowler mg, huang 
s, sperling rs, cunningham b, gandia j, maupin r, zorrilla cd, jones t,
o'sullivan mj; pediatrics aids clinical trials group 288 protocol team.

author information: 
(1)university medicine dentistry new jersey, newark, new jersey 07103, 
usa. bardegad@umdnj.edu

zidovudine prophylaxis recommended reduce perinatal hiv-1 transmission, but
there limited data long-term effects women's health. pediatrics aids
clinical trials group (pactg) 288 prospective observational study among us 
women randomized zidovudine placebo pactg 076 designed to
evaluate compare postpartum clinical, immune, viral parameters between
randomized treatment arms. forty-eight percent (226/474) eligible women
enrolled study (mean follow-up 4.1 years). progression time aids
or death similar groups, observed 21 (19%) zidovudine group women
and 29 (25%) placebo group women (rr = 0.73, 90% ci: 0.46-1.17). significant
differences cd4 lymphocyte count hiv rna levels detected. genotypic
zidovudine resistance detected 10% 156 women (9% zidovudine group
women 11% placebo group women). based data, zdv monotherapy could
be considered chemoprophylaxis reduce perinatal hiv transmission for
minimally symptomatic hiv-infected pregnant women low viral load and
normal cd4 cell count want receive highly active antiretroviral
therapy concern potential side effects wish reduce
fetal exposure multiple drugs pregnancy.

doi: 10.1097/00126334-200302010-00009 
pmid: 12571527  [indexed medline]

